<DOC>
	<DOCNO>NCT01760772</DOCNO>
	<brief_summary>Individuals obesity increase risk heart disease diabetes . There current drug market target hormone , Glucagon like peptide-1 ( GLP-1 ) treat diabetes . The investigator want determine target hormone also help people high cholesterol triglyceride . In study , investigator look role GLP-1 healthy subject subject bariatric surgery .</brief_summary>
	<brief_title>Effect GLP-1 Postprandial Lipid Metabolism</brief_title>
	<detailed_description>Major consequence global pandemic obesity include cardiovascular disease , type 2 diabetes dyslipidemia . The dyslipidemia obesity commonly consist fast hypertriglyceridemia increase plasma low-density lipoprotein ( VLDL ) , reduce high-density lipoprotein ( HDL ) presence small , dense low-density lipoprotein ( LDL ) . However , recently , increase secretion intestinally derive lipoprotein ( LPs ) recognize contribute dyslipidemic profile postprandial lipemia link adverse health outcome . Glucagon-like peptide-1 ( GLP-1 ) , hormone secrete meal absorption play key role control plasma glucose implicated candidate hormone regulate intestinal lipid metabolism . Studies rodents demonstrate treatment GLP-1R agonist ; exendin-4 ( Ex-4 ) reduce postprandial chylomicron ( CM ) production CM-associated cholesterol triglyceride ( TG ) . Similar result find Type 2 diabetes ( T2D ) subject treated Ex-4 ; report reduction intestinally derive LP production total plasma TG . The objective study determine whether GLP-1 involve physiologic regulation postprandial lipid metabolism healthy woman , test hypothesis improve lipid parameter find overweight woman bariatric surgery mediate GLP-1 . The specific aim project 1 ) determine either pharmacologic treatment GLP-1 and/or antagonism endogenous GLP-1 activity improve postprandial lipid metabolism healthy subject 2 ) determine role elevate postprandial GLP-1 level lipid metabolism obese subject sleeve gastrectomy . The investigator use infusion synthetic GLP-1 native hormone confirm lipid-lowering result publish use pharmacologic GLP-1 receptor ( GLP-1R ) agonists . The investigator also use GLP-1R antagonist exendin- ( 9-39 ) determine role endogenous GLP-1 lipemia test meal . A demonstration physiologic action would expand current understanding lipid metabolism , provide new insight effect bariatric surgery , allow design refine , mechanistic study process . In addition , potential GLP-1R signal promote lipid metabolism direct translational importance therapy already exist could capitalize mechanism . Understanding role GLP-1R regulation lipid absorption clearance could lead appropriate target GLP-1 base drug specific diabetic patient , i.e . one problematic dyslipidemia high risk cardiovascular disease . Moreover , understanding effect GLP-1 plasma lipid could eventually lead new approach treat nondiabetic dyslipidemic person .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>Aim 1 : Healthy , normolipemic men postmenopausal woman ; age 4060 year ; BMI 2535 Aim 2 : Men postmenopausal woman successful vertical sleeve gastrectomy ( VSG ) surgery age weightmatched nonsurgical control men postmenopausal woman ; age 406 year ; BMI 2835 ; steady weight least 3 month prior study Exclusion Criteria Aim 1 : History clinical evidence impair fast glucose diabetes mellitus , myocardial infarction symptom congestive heart failure , history active liver renal disease , calculate glomerular filtration rate &lt; 60 mL/min ) . History extreme dyslipidemia ( i.e . familial hypercholesterolemia ) Cardiovascular disease ( CVD ) . Fasting plasma total cholesterol &gt; 200 mg/dL fast plasma TGs &gt; 150 mg/dL . Surgery within 6 month . Pregnancy lactation . Anemia define hematocrit &lt; 33 % . History cancer anorexia nervosa GI disorder . Use medication alter insulin sensitivity ( i.e . niacin , glucocorticoid , metformin ) lipid metabolism ( i.e . statin , niacin , fibrate , ezetimibe ) . Plasma HbA1c &gt; 6.0 . Fasting glucose &gt; 110 mg/dL Electrocardiogram ( ECG ) abnormality : evidence ischemia arrhythmia . Exclusion Criteria Aim 2 : History CVD . Fasting plasma total cholesterol &gt; 250 mg/dL fast plasma TGs &gt; 300 mg/dL . Surgical intervention within 6 month . Anemia define hematocrit &lt; 33 % . History cancer anorexia nervosa major GI disease surgery . Use medication alter insulin sensitivity ( i.e . niacin , glucocorticoid , metformin ) lipid metabolism ( i.e . statin , ezetimibe ) . HbA1c &gt; 6.0 . Fasting glucose &gt; 110 mg/dL Electrocardiogram ( ECG ) abnormality : evidence ischemia arrhythmia . Significant renal , hepatic pulmonary disease .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>heart disease</keyword>
	<keyword>GLP-1</keyword>
	<keyword>Exendin-9</keyword>
	<keyword>postprandial lipid</keyword>
</DOC>